CA2164324A1 - Generation concentration and efficient transfer of vsv-g pseudotyped retroviral vectors - Google Patents
Generation concentration and efficient transfer of vsv-g pseudotyped retroviral vectorsInfo
- Publication number
- CA2164324A1 CA2164324A1 CA002164324A CA2164324A CA2164324A1 CA 2164324 A1 CA2164324 A1 CA 2164324A1 CA 002164324 A CA002164324 A CA 002164324A CA 2164324 A CA2164324 A CA 2164324A CA 2164324 A1 CA2164324 A1 CA 2164324A1
- Authority
- CA
- Canada
- Prior art keywords
- vectors
- retroviral
- cells
- present application
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 title abstract 8
- 230000001177 retroviral effect Effects 0.000 title abstract 6
- 102100021696 Syncytin-1 Human genes 0.000 abstract 3
- 101710091045 Envelope protein Proteins 0.000 abstract 2
- 101710188315 Protein X Proteins 0.000 abstract 2
- 241000251468 Actinopterygii Species 0.000 abstract 1
- 241000699800 Cricetinae Species 0.000 abstract 1
- 101710121417 Envelope glycoprotein Proteins 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 241000711975 Vesicular stomatitis virus Species 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000005199 ultracentrifugation Methods 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present application discloses retrovirus-derived vectors in which the retroviral envelope glycoprotein has been replaced by the G
glycoprotein of vesicular stomatitis virus, and the use of these vectors in the transfer of exogenous genes into the cells of a wide variety of non-mammalian organisms. Also disclosed is a method for the generation of retroviral vectors in high titers, wherein a recombinant, stable host cell line is provided which harbors the retroviral vector of interest without envelope protein. High-titer retroviral vector production is initiated by introducing nucleic acid encoding a functional membrane-associated protein into the cell line. The vectors disclosed in the present application can be concentrated by ultracentrifugation to titers greater than 10 9 cfu/ml which are especially useful in human gene therapy trials, and can also infect cells, such as hamster and fish cells, that are ordinarily resistant to infection with vectors containing the retroviral envelope protein.
glycoprotein of vesicular stomatitis virus, and the use of these vectors in the transfer of exogenous genes into the cells of a wide variety of non-mammalian organisms. Also disclosed is a method for the generation of retroviral vectors in high titers, wherein a recombinant, stable host cell line is provided which harbors the retroviral vector of interest without envelope protein. High-titer retroviral vector production is initiated by introducing nucleic acid encoding a functional membrane-associated protein into the cell line. The vectors disclosed in the present application can be concentrated by ultracentrifugation to titers greater than 10 9 cfu/ml which are especially useful in human gene therapy trials, and can also infect cells, such as hamster and fish cells, that are ordinarily resistant to infection with vectors containing the retroviral envelope protein.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7320993A | 1993-06-04 | 1993-06-04 | |
| US08/073,209 | 1993-06-04 | ||
| US08/104,804 | 1993-08-10 | ||
| US08/104,804 US5512421A (en) | 1991-02-19 | 1993-08-10 | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
| PCT/US1994/006272 WO1994029440A1 (en) | 1993-06-04 | 1994-06-03 | Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2164324A1 true CA2164324A1 (en) | 1994-12-22 |
| CA2164324C CA2164324C (en) | 2005-12-06 |
Family
ID=35519634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002164324A Expired - Lifetime CA2164324C (en) | 1993-06-04 | 1994-06-03 | Generation concentration and efficient transfer of vsv-g pseudotyped retroviral vectors |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2164324C (en) |
-
1994
- 1994-06-03 CA CA002164324A patent/CA2164324C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2164324C (en) | 2005-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0702717A4 (en) | Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors | |
| CA2177085C (en) | Adenovirus e1-complementing cell lines | |
| NZ269019A (en) | Method of inducing transduction with retroviral assistance | |
| AU4545889A (en) | Synthetic dna derived recombinant hiv antigens | |
| CA2164818A1 (en) | Tandem synthetic hiv-1 peptides | |
| CA2222129A1 (en) | A method for producing influenza hemagglutinin multivalent vaccines | |
| DE68929343T2 (en) | Modified cells with resistance to retroviral infections | |
| Dotto et al. | Replication of a plasmid containing two origins of bacteriophage f1 | |
| CA2223433A1 (en) | Ob protein compositions and methods | |
| EP0500917A4 (en) | Recombinant herpes simplex viruses vaccines and methods | |
| JP2004508064A5 (en) | ||
| CA2145641A1 (en) | Pseudo-adenovirus vectors | |
| DE68929521D1 (en) | Non-nuclear chromosomal transformation | |
| IL79522A0 (en) | Fusion proteins,process for their preparation and their use | |
| GR940300052T1 (en) | Protein having cytokin type activity, recombinant DNA coding for this protein, transformed cells and microorganisms. | |
| CA2066618A1 (en) | Plasmids containing dna encoding the amino acid sequence of tcf-ii, transformed cells with the plasmids, and production method of biologically active substance using the transformed cells | |
| DK0632129T3 (en) | Recombinant foamy virus vectors for medical and diagnostic use, and methods for preparing recombinant foamy virus vectors | |
| NO891662D0 (en) | PROCEDURE FOR PURIFICATION OF HOSE POISON POLYPEPTIDES, COMPOUNDS AND EXPRESSION VECTORS FOR PREPARATION OF POLYPEPTIDES. | |
| Cretin et al. | Complete cDNA sequence of sorghum phosphoenolpyruvate carboxylase involved in C4 photosynthesis. | |
| CA2557882A1 (en) | Defective packaging non-oncoviral vectors based on mpmv and hiv | |
| CA2019803A1 (en) | Feline interferon and process for production thereof | |
| CA2082042A1 (en) | Production of plants resistant to attacks of sclerotinia sclerotiorum by introducing a gene coding for an oxalate oxidase | |
| CA2164324A1 (en) | Generation concentration and efficient transfer of vsv-g pseudotyped retroviral vectors | |
| CA2163081A1 (en) | Thermoresistant Alpha-1-Antitrypsin Mutein | |
| DE69318716T2 (en) | Anti-cat immunodeficiency virus (FIV) vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20140603 |